Optical

UnitedHealthcare Vision Plans Again Rank Highest in Customer Satisfaction in J.D. Power Report

Retrieved on: 
Thursday, February 14, 2019
Health, Optical, Professional services, Insurance, General Health, Managed care, Services marketing, Customer satisfaction, UnitedHealth Group, Business

UnitedHealthcare Vision plans tied for highest in customer satisfaction among the nations vision carriers, according to the J.D.

Key Points: 
  • UnitedHealthcare Vision plans tied for highest in customer satisfaction among the nations vision carriers, according to the J.D.
  • This marks the fifth time in six years that UnitedHealthcare Vision has earned the highest ranking among vision plans.
  • View the full release here: https://www.businesswire.com/news/home/20190214005153/en/
    UnitedHealthcare again ranked highest in customer satisfaction by J.D.
  • This years independent report is based on responses from more than 1,000 vision plan participants nationwide, measuring customer satisfaction based on five factors: communication, plan coverage, plan cost, customer service experience, and claims and reimbursement experience.

Visioneering Technologies, Inc. Selects Positive Impact (Sales) Ltd. to Distribute NaturalVue Multifocal Lenses in the United Kingdom

Retrieved on: 
Thursday, February 14, 2019
Health, Medical devices, Optical, Medical Supplies, General Health, Corrective lenses, VTI, Lens, Contact lens

Visioneering Technologies, Inc., (VTI) has selected Positive Impact as the companys latest Authorized Distributor partner for the NaturalVue (etafilcon A) Brand 1 Day Contact Lenses.

Key Points: 
  • Visioneering Technologies, Inc., (VTI) has selected Positive Impact as the companys latest Authorized Distributor partner for the NaturalVue (etafilcon A) Brand 1 Day Contact Lenses.
  • Positive Impact (PI), based in Hastings, is a distributor of leading eye care products and contact lenses throughout the United Kingdom.
  • Were thrilled to be working with Positive Impact, said Tony Sommer, Senior Vice President of Global Sales and Marketing for VTI.
  • Managing Director, Maxine Green commented, "Positive Impact is delighted to have been selected by VTI to represent NaturalVue in the UK.

Conjunctivitis Therapeutics Markets, 2023 - Dominated by Akorn Incorporated, Allergan, Bausch Health, Novartis, and Santen Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 13, 2019
Health, Optical, Pharmaceutical, Medicine, Health, RTT, Medical specialties, Conjunctivitis, Measles, Antibiotic, Eye drop, Antibiotics, Pharmaceuticals policy

The conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.

Key Points: 
  • The conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.
  • The ease of availability of antibiotic eye drops and ointments for the treatment of bacterial conjunctivitis and antibiotics for viral conjunctivitis is leading to an increase in the use of these therapeutics.
  • The use of therapeutics is primarily to avoid the progression of the disease into severe indications, which could increase the economic burden of patients.
  • One of the major challenges faced by the global conjunctivitis therapeutics market is the patent expiration of various drugs in the market.

Retinopathy - Global Partnering, 2012 to 2018 (2019 Update): Trends in Partnering Deals, Top Deals by Value - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 12, 2019
Health, Optical

The "Global Retinopathy Partnering 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Retinopathy Partnering 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.
  • The report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
  • Deals listed by company A-Z, industry sector, stage of development, technology type
    The report provides an analysis of partnering deals.
  • The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology.

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors

Retrieved on: 
Tuesday, February 12, 2019
Health, Biotechnology, Optical, Pharmaceutical, Board of directors, Business law, Committees, Corporate law, Business, Law, Private law

Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors.
  • Were pleased to welcome Tom to our board and look forward to working closely with him.
  • Im excited to join the Omeros board, and I look forward to helping the company continue advancing and commercializing its portfolio of cutting-edge assets.
  • Dr. Bumol serves on the University of Michigan Technology Transfer National Advisory Board, on the Board of Directors of Pantheryx, and as an advisor to Lilly Ventures.

BostonSight® Promotes Sara Yost to CEO

Retrieved on: 
Tuesday, February 12, 2019
Practice Management, Health, Optical, Chief financial officer

BostonSight , an international leader in the treatment of patients with complex corneal disease, today announced that its CFO, Sara Yost, will be promoted to CEO effective March 11, 2019.

Key Points: 
  • BostonSight , an international leader in the treatment of patients with complex corneal disease, today announced that its CFO, Sara Yost, will be promoted to CEO effective March 11, 2019.
  • Gene Guselli joined BostonSight as President and CEO in April 2016.
  • Sara Yost has been with BostonSight since 2002, holding several positions in administration, finance and operations, including the past three years as CFO.
  • Saras unparalleled knowledge of the BostonSight organization and industry, coupled with the deep relationships she has formed with its employees and network partners made Sara the ideal choice to succeed Gene as CEO, said David Rosenbloom, PhD, Chairman of the Board at BostonSight.

Pr3vent, Inc. Completes Series A Financing Led By InFocus Capital Partners

Retrieved on: 
Tuesday, February 12, 2019
Technology, Data management, Hardware, Software, Health, Medical devices, Optical, Baby, Maternity, Communications, Public relations, Investor relations, Consumer, General Health, Finance, Money, Economy, InFocus, Venture capital

Pr3vent, Inc ., a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners, a venture capital fund specializing in the identification, capitalization and development of breakthrough and disruptive opportunities in the ophthalmic space.

Key Points: 
  • Pr3vent, Inc ., a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners, a venture capital fund specializing in the identification, capitalization and development of breakthrough and disruptive opportunities in the ophthalmic space.
  • We value the companys innovative AI platform and understand the importance of helping it succeed, stated Ron Weiss, MD, managing partner of InFocus Capital Partners.
  • InFocus Capital Partners Series A financing will help accelerate the processes of developing our revolutionary imaging system for early detection of preventable vision loss in newborns.
  • InFocus Fund I is a venture capital fund specializing in the identification, capitalization and development of breakthrough and disruptive opportunities in the ophthalmic space.

STAAR Surgical Announces Strategic Cooperation Agreement With the Smile Eyes Group in Germany and Austria

Retrieved on: 
Tuesday, February 12, 2019
Surgery, Health, Medical devices, Optical, Eye surgery, Corrective lenses

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced a Strategic Cooperation Agreement with the Smile Eyes Group, an alliance of more than 80 eye experts across 13 vision correction eye centers in Germany and Austria.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced a Strategic Cooperation Agreement with the Smile Eyes Group, an alliance of more than 80 eye experts across 13 vision correction eye centers in Germany and Austria.
  • The central hole of the EVO lens allows for the eyes natural nourishing aqueous flow and a single surgical procedure.
  • In 2016 STAAR Surgical Company announced the first Strategic Cooperation Agreements with customers that now serves as the model for how the Company conducts business.
  • We look forward to working closely with the Smile Eyes Group on patient education, marketing, and surgeon training under this new strategic cooperation agreement.

GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology

Retrieved on: 
Tuesday, February 12, 2019
Health, Biotechnology, Clinical trials, Genetics, Optical, Pharmaceutical, Health, Articles, Epidemiology, Nursing research, Clinical trial, Design of experiments, Pharmaceutical industry, Product testing

This study demonstrates that GS010 (rAAV2/2-ND4) is both safe and well tolerated 2 years after a single unilateral intravitreal administration.

Key Points: 
  • This study demonstrates that GS010 (rAAV2/2-ND4) is both safe and well tolerated 2 years after a single unilateral intravitreal administration.
  • The study was an open-label single-center Phase I/II clinical trial that included 4 dose-escalation cohorts and an extension cohort.
  • The study design included an initial follow-up period of 48 weeks, followed by longer-term follow-up for an additional 4 years.
  • The primary objective was to ascertain the safety and tolerability of escalating doses of rAAV2/2-ND4.

Worldwide Intraocular Lenses (IOL) Market Report, 2019 - Alcon, Bausch + Lomb and J&J Vision Care are Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, February 11, 2019
Health, Optical, Eye surgery, Glued IOL

Rising Incidence of Vision Disorders and the Subsequent Need for Vision Correction Procedures: A Business Case for Ocular Products

Key Points: 

Rising Incidence of Vision Disorders and the Subsequent Need for Vision Correction Procedures: A Business Case for Ocular Products
Healthcare Spending & General Economy: Key Determinations of Growth in IOL Market